Lantern Pharma is Changing How We Think About Drug Discovery

Before 2024, Lantern Pharma (NASDAQ:LTRN) was relatively unnoticed in the biotech sector. It was merely a nano-cap biotech stock that was indistinguishable from a very crowded pool of other low-cap stocks vying for investor attention. But over the past six months, LTRN stock soared more than 175% due to the advancement of five of its leading drug candidates into clinical...

Markets

Html code here! Replace this with any non empty raw html code and that's it.

Today's Headlines

About StockBase

Thank you for joining us at StockBase.com! We strive to be one of the most unbiased and trustworthy sources for your stock market and financial updates. Our team of analysts are seasoned with years of experience and take pride in serving useful updates to our readers.